Related references
Note: Only part of the references are listed.KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
Wenting Liao et al.
CANCER CELL (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Contribution of Epithelial Plasticity to Therapy Resistance
Patricia G. Santamaria et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H
Matthew A. Gubens et al.
LUNG CANCER (2019)
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Lillian Sun et al.
JCI INSIGHT (2019)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Karin M. Knudson et al.
ONCOIMMUNOLOGY (2018)
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
Michael Carleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
Caroline Jochems et al.
ONCOTARGET (2017)
Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis
Keiichi Asano et al.
SCIENTIFIC REPORTS (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
Rahima Jamal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer
Charli Dominguez et al.
JCI INSIGHT (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Yanyan Lou et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
Chan-Young Ock et al.
ONCOTARGET (2016)
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Romaine I. Fernando et al.
ONCOTARGET (2016)
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
Jordan Kardos et al.
JCI INSIGHT (2016)
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
Justin M. David et al.
VACCINES (2016)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
Versican silencing improves the antitumor efficacy of endostatin by alleviating. its induced inflammatory and immunosuppressive changes in the tumor microenvironment
Zi Wang et al.
ONCOLOGY REPORTS (2015)
TGF-beta Activation and Function in Immunity
Mark A. Travis et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
Suling Liu et al.
CANCER RESEARCH (2011)
IL-8 Signaling Plays a Critical Role in the Epithelial-Mesenchymal Transition of Human Carcinoma Cells
Romaine I. Fernando et al.
CANCER RESEARCH (2011)
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Christophe Ginestier et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
Tumor-derived TGF-beta Mediates Conversion of CD4(+)Foxp3(+) Regulatory T Cells in a Murine Model of Pancreas Cancer
Tricia A. Moo-Young et al.
JOURNAL OF IMMUNOTHERAPY (2009)
The Interleukin-8 Pathway in Cancer
David J. J. Waugh et al.
CLINICAL CANCER RESEARCH (2008)
Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival
IH Benoy et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
